Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1986 1
1987 2
1988 4
1989 2
1990 4
1991 8
1992 8
1993 10
1994 9
1995 14
1996 3
1997 6
1998 7
1999 9
2000 6
2001 5
2002 10
2003 8
2004 10
2005 10
2006 3
2007 13
2008 23
2009 26
2010 17
2011 17
2012 26
2013 30
2014 39
2015 51
2016 56
2017 72
2018 135
2019 218
2020 426
2021 637
2022 675
2023 847
2024 339

Text availability

Article attribute

Article type

Publication date

Search Results

3,349 results

Results by year

Filters applied: . Clear all
Page 1
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lordick F, et al. Ann Oncol. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. Epub 2022 Jul 29. Ann Oncol. 2022. PMID: 35914639 Free article. No abstract available.
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, Iijima K, Koike T, Omura N, Nomura T, Kawamura O, Ohara S, Ozawa S, Kinoshita Y, Mochida S, Enomoto N, Shimosegawa T, Koike K. Iwakiri K, et al. J Gastroenterol. 2022 Apr;57(4):267-285. doi: 10.1007/s00535-022-01861-z. Epub 2022 Feb 28. J Gastroenterol. 2022. PMID: 35226174 Free PMC article. Review.
The important clinical issues addressed in the present revision are (i) the introduction of treatment algorithms that classify GERD into reflux esophagitis and non-erosive reflux disease, (ii) the clarification of treatment algorithms based on to the severity of reflux eso …
The important clinical issues addressed in the present revision are (i) the introduction of treatment algorithms that classify GERD into ref …
Teserpaturev/G47Δ: First Approval.
Frampton JE. Frampton JE. BioDrugs. 2022 Sep;36(5):667-672. doi: 10.1007/s40259-022-00553-7. BioDrugs. 2022. PMID: 36098872 Review.
Teserpaturev/G47delta (Delytact()) is a third-generation (triple-mutated) recombinant oncolytic herpes simplex virus type 1 being developed by Daiichi Sankyo Co., Ltd. for the treatment of certain solid cancers. Teserpaturev/G47delta has been approved for the treatment of …
Teserpaturev/G47delta (Delytact()) is a third-generation (triple-mutated) recombinant oncolytic herpes simplex virus type 1 being developed …
Systemic lupus erythematosus.
Tanaka Y. Tanaka Y. Best Pract Res Clin Rheumatol. 2022 Dec;36(4):101814. doi: 10.1016/j.berh.2022.101814. Epub 2023 Jan 24. Best Pract Res Clin Rheumatol. 2022. PMID: 36702700 Review.
Promising approaches include the development of a Janus kinase inhibitors targeting tyrosine kinase deucravacitinib, plasmacytoid dendritic cell-targeted drugs, proteasome inhibitors (e.g., iberdomide), type II anti-CD20 antibody, and obinutuzumab....
Promising approaches include the development of a Janus kinase inhibitors targeting tyrosine kinase deucravacitinib, plasmacytoid dendritic …
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. DiNardo CD, et al. J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043428 Free PMC article. Clinical Trial.
Relapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic options. This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined wi …
Relapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic options. This phase Ib/ …
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Jänne PA. Yu HA, et al. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10. J Clin Oncol. 2023. PMID: 37689979 Free PMC article. Clinical Trial.
We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). METHODS: This phase II study (ClinicalTrials.gov identifier: NCT04619004) was designed to evaluate HER3-DXd in patients with …
We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer …
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Subbiah V, et al. Ann Oncol. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014. Epub 2022 Jan 10. Ann Oncol. 2022. PMID: 35026411 Free PMC article. Clinical Trial.
BACKGROUND: Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort of the phase II Rare …
BACKGROUND: Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic …
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.
Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Falanga A, et al. Ann Oncol. 2023 May;34(5):452-467. doi: 10.1016/j.annonc.2022.12.014. Epub 2023 Jan 10. Ann Oncol. 2023. PMID: 36638869 Free article. No abstract available.
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Davis LE, et al. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23. J Clin Oncol. 2019. PMID: 31013172 Free PMC article. Clinical Trial.
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. ...
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanc …
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Rugo HS, et al. ESMO Open. 2022 Aug;7(4):100553. doi: 10.1016/j.esmoop.2022.100553. Epub 2022 Aug 11. ESMO Open. 2022. PMID: 35964548 Free PMC article. Review.
INTRODUCTION: The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) targets human epidermal growth factor receptor 2 (HER2) and has been evaluated in patients with HER2-positive unresectable/metastatic breast cancer in the phase II DESTINY-Breast01 trial (NCT03248492; …
INTRODUCTION: The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) targets human epidermal growth factor receptor 2 (HER2) and has bee …
3,349 results